InflaRx N.V. IFRX 深 滬
已收盤 02-06 16:00:00 美东时间
0.8949
+0.070
+8.42%
華盛通- 最 高0.90
- 今 開0.8449
- 成交量 63.86万股
- 最 低 0.8263
- 昨 收 0.8254
- 總市值 6062.69万
- 52周最高 2.02
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 0.7113
- 委 比 -84.96%
- 總股本 6774.71万
- 歷史最高 53.10
- 量 比 1.25
- 振 幅 8.93%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多InflaRx Announces Participation in February Investor Conferences
InflaRx N.V. will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12 in New York with a fireside chat at 11:30 AM ET, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26 in a virtual format with a presentation at 8:40 AM ET. The company will also hold one-on-one investor meetings on both dates. Links to view the sessions are avail...
01-29 12:30
InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway
InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.
01-09 01:22
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
InflaRx prioritizes izicopan as its lead asset, aiming for HS Phase 2b readiness and expanding signal-finding activities in inflammation and immunology through a China PK bridging study. The company is reducing its workforce by ~30%, cutting costs to extend its cash runway to mid-2027, and planning a 2026 capital markets day to showcase izicopan's potential. Izicopan, an oral C5aR inhibitor, shows promise in HS and CSU, with plans for additional ...
01-08 13:00
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
InflaRx Outlined Multiple Data Analyses Of The Phase 3 Study For Vilobelimab In Pyoderma Gangrenosum, Which Was Terminated Earlier In 2025 After An Independent Data Monitoring Committee Recommended To Stop The Trial Early Due To Futility
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc
2025-12-30 20:32
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
The Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) was terminated due to futility, but subsequent analyses indicate potential efficacy, particularly in ulcer volume reduction. InflaRx plans to discuss a development path with the FDA, possibly in collaboration with a partner. The study enrolled 54 patients, with positive trends in secondary endpoints and tolerability. Post-hoc analyses showed significant treatment effects in ulcer volu...
2025-12-30 12:30
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
InflaRx N.V. announced that the WHO granted the INN name "izicopan" to its orally available C5aR inhibitor, formerly INF904. CEO Prof. Niels C. Riedemann highlighted the promising clinical data in hidradenitis suppurativa and chronic spontaneous urticaria, showcasing izicopan's potential to address significant unmet needs in both diseases. Izicopan, an oral C5aR inhibitor, has demonstrated best-in-class potential with favorable safety and efficac...
2025-12-11 12:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
2025-12-05 20:05
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
Leerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Market Perform and lowers the price target from $5 to $2.
2025-12-03 21:37
